Clinical trials: Visual Loss
Retinitis Pigmentosa
Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa
Retinitis Pigmentosa (RP) patients are interested in trying alternative therapies to attempt to slow, halt or reverse the retinal disease process, and claim success with some approaches such as acupuncture, but this potential…
- Trial name
- NCT01604356
- Testing
- Electro-acupuncture
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic…
- Trial name
- NCT06792500
- Testing
- Glycerol Tributyrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- George Washington University
Behavioral Dynamics, Visual Impairment
Behavioral Dynamics Between Infants With Visual Loss and Healthy Controls
An individual senses the world and reflects feedbacks via independent behaviors. Such precise collaboration of the sensory and behavioral systems is fundamental to survival and evolution.
- Trial name
- NCT03431207
- Testing
- Standardized video recording for behaviors
- Where
- China
- Volunteers
- 4,196 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Macular Degeneration, Central Visual Impairment
Scotoma Perimetry Oculomotor Training
The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals…
- Trial name
- SPOT (NCT05456581)
- Testing
- 'Scotoma awareness' Training, Control Training
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Optic Neuritis, Multiple Sclerosis
Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON)
3D FLAIR, 3D T1 FAT SAT, coronal T2 and coronal T1 dixon sequences were usually used to assess visual deficits in MRI. Optic nerve examination is preferably performed using a coronal T2 sequence in order to detect a hypersignal…
- Trial name
- COCON (NCT04793087)
- Testing
- Magnetic Resonance Imaging
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RIDE (NCT00473382)
- Testing
- Ranibizumab
- Volunteers
- 382 people
- Sponsor
- Genentech, Inc.
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Retinitis Pigmentosa
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow.
- Trial name
- BMSCRP1 (NCT04925687)
- Testing
- Intravitreal autologous CD34+ cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Davis
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Glaucoma, Visual Impairment
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
Falls are one of the most serious public health concerns for seniors, with significant medical and economic consequences. This concern is even higher in patients with peripheral field loss due to glaucoma because of the patients'…
- Trial name
- NCT06000865
- Testing
- Action video game training, Conventional physical training
- Where
- Hong Kong
- Volunteers
- 56 people
- Sponsor
- The Hong Kong Polytechnic University
Vision Impairment and Blindness, Glaucoma
Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice
In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition.
- Conditions
- Vision Impairment and Blindness, Glaucoma, Age-Related Macular Degeneration, Cataract
- Trial name
- DETECT (NCT07015034)
- Testing
- focus on vision impairment in older patients in general practice
- Where
- 2 sites in Denmark
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Dry Eye Syndromes, Cataract
Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients
Clinical trial with medical devices, post-authorization, parallel, single-blind, randomized, comparative, prospective to study how afects the quality of life the use of ocular eye drops on patients with dry eye symptomatology and…
- Trial name
- NCT04063644
- Testing
- Vis Glyc Neo, Physiological saline solution
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Homonymous Hemianopia
Assessment of Homonymous Visual Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)
The purpose of this explorative study, targeting subjects with homonymous visual field loss, is threefold: (i) to identify the perimetric / psychophysical method, that is most closely correlated with an individually assessed…
- Trial name
- Hemi-Drive (NCT01372332)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Age-Related Neovascular Macular Degeneration
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related…
- Trial name
- VIBERA (NCT00559715)
- Testing
- bevacizumab, ranibizumab
- Where
- Germany
- Volunteers
- 366 people
- Sponsor
- Klinikum Bremen-Mitte, gGmbH
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Macular Degeneration, Diabetic Retinopathy
Iopidine to Decrease Intraocular Pressure Rise After Injections
This is a prospective, randomized, controlled, open-label, single-site investigator-initiated clinical trial. A total of 120 participants will be randomized in a 1:1 ratio either to receive one drop of apraclonidine 1% ophthalmic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07891910
- Testing
- Apraclonidine 1.0% ophthalmic solution
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Retina Consultants of Delmarva
Macular Degeneration
Investigating Optical and Neural Causes of Vision Loss
With the aging of the population, the prevalence of age-related macular degeneration (AMD) eye disease has resulted in a large number of people suffering from central vision loss.
- Trial name
- NCT00926913
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Stroke, Ischemic, Quadrantanopia
Visual Rehabilitation After Occipital Stroke
This research aims to examine changes in plastic potential of the visual system with time from stroke affecting primary visual cortex.
- Conditions
- Stroke, Ischemic, Quadrantanopia, Vision Loss Partial, Visual Field Defect, Peripheral
- Trial name
- NCT04798924
- Testing
- Subacute Training in the intact field, Subacute Training in the blind field, Chronic Training in the blind field
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester